2005
DOI: 10.1021/pr050149f
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Cancer Proteomics:  Promises and Pitfalls

Abstract: Proteome analysis promises to be valuable for the identification of tissue and serum biomarkers associated with human malignancies. In addition, proteome technologies offer the opportunity to analyze protein expression profiles and to analyze the activity of signaling pathways. Many published proteomic studies of human tumor tissue are associated with weaknesses in tumor representativity, sample contamination by nontumor cells and serum proteins. Studies often include a moderate number of tumors which may not … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
65
0

Year Published

2005
2005
2014
2014

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 94 publications
(65 citation statements)
references
References 109 publications
0
65
0
Order By: Relevance
“…Most of the regulatory proteins involved in cancer progression are present at very low concentrations (ng mL -1 or pg mL -1 ) and may be masked by the presence of higher abundant proteins, interfering with the identification and quantification of these low abundant regulatory proteins [63]. Several combinations of pre-fractionation techniques can deplete these high abundant proteins and can also remove excess salts and lipids from serum sampleSerum biomarkers can be of three types: 1. serum proteins that are differentially expressed, or cleaved or modified in cancer patients; 2. proteins that are secreted by the tumor cells into circulation; or 3. intracellular tumor proteins that are released when tumor cells die [64]. Presently only a few blood biomarkers have proven useful for diagnosis of primary cancers.…”
Section: Serum Based Protein Biomarkersmentioning
confidence: 99%
“…Most of the regulatory proteins involved in cancer progression are present at very low concentrations (ng mL -1 or pg mL -1 ) and may be masked by the presence of higher abundant proteins, interfering with the identification and quantification of these low abundant regulatory proteins [63]. Several combinations of pre-fractionation techniques can deplete these high abundant proteins and can also remove excess salts and lipids from serum sampleSerum biomarkers can be of three types: 1. serum proteins that are differentially expressed, or cleaved or modified in cancer patients; 2. proteins that are secreted by the tumor cells into circulation; or 3. intracellular tumor proteins that are released when tumor cells die [64]. Presently only a few blood biomarkers have proven useful for diagnosis of primary cancers.…”
Section: Serum Based Protein Biomarkersmentioning
confidence: 99%
“…The complexity of human diseases presents another degree of challenge. For example, in human cancer, each tumor type typically consists of a number of subtypes that differ with regard to their spectrum of genetic alterations (107). Therefore, a potential candidate biomarker of disease may be elevated only in a certain percentage of the pool of disease patients.…”
Section: Implications Of Human Heterogeneity In Clinical Proteomics Smentioning
confidence: 99%
“…While plasma is the most important and readily available source for systemic biomarkers, other biological matrices have been explored to screen for biomarkers that are expected to operate at a more local level. Some examples of such alternative biological matrices are tumor tissue [4], cerebrospinal fluid [5], and suction blister fluid [6].…”
Section: Introductionmentioning
confidence: 99%